Abstract:Graft versus Host Disease (GVHD) and infectious complications are the main cause of morbidity and mortality after allogeneic blood or marrow transplantation (allo-BMT). Currently, there is no objective laboratory assay to assess the level of immunereactivity to potentially predict the risk of complications in allo-BMT patients. The Cylex ImmuKnow™ assay is approved by the US Food and Drug Administration for detection of cell mediated immunity in immunosuppressed individuals. This assay measures immune response to stimulation by detecting ATP synthesis in CD4 T cells following phytohemagglutinin (PHA) stimulation. We prospectively studied PHA-induced ATP release in 20 allo-BMT patients weekly from day +15 until day +100 post-transplantation. We tested 224 blood samples with an average of 11.2 per patient (SD 1.8). Patients received grafts from matched unrelated (MUD, n=11 [55%]), matched related (MRD, n=8 [40]) and syngeneic donors (n=1). Myeloablative and nonmyeloablative conditioning regimens were used in 13 (65%) and 7 (35%) patients, respectively. 12 patients (60%) developed GVHD requiring treatment, 2 (10%) developed GVHD which did not require treatment, and 6 (30%) did not develop any GVHD. Cyclosporine levels (n=19) did not correlate with ATP response, nor did the graft composition (CD34+ cells/kg or the CD3+ cells/kg). Further, we determined that the maximum ATP level was not a significant predictor of GVHD incidence, nor was the maximum fold increase over baseline. However, we observed worse outcomes in patients who had sustained low ATP levels as defined by 3 consecutive measurements of ATP <75 ng/mL. We found a significant correlation between persistently suppressed ATP levels and death (p=0.013). In all patients who died (n=7), ATP levels were persistently low and did not recover. In contrast, all 9 patients who exhibited ATP levels >75ng/ml are alive. Patients who maintained an average of >100 ng/ml ATP (mean 235 ng/ML, range 114-402 ng/mL) at monthly intervals did not have GVHD (n=6) or require therapy for GVHD (n=2). Conversely, patients with ATP levels <100 ng/mL at monthly intervals were treated for GVHD (mean 84.4 ng/mL, range 24-318ng/mL). Our data suggest that a persistent immunocompromised state in BMT recipients is associated with poor outcome. A larger study is warranted to analyze the utility of the Cylex ImmuKnow™ assay in BMT patients, which may enable us to predict outcomes and tailor immunosuppressive therapy.

An Immune Function Assay Predicts Post-Transplant Recurrence in Patients with Hepatocellular Carcinoma

Application of immune cell functional assay in monitoring immune status in renal transplant recipients

Relationship between the ATP level in CD4+ T lymphocyte and recurrence of hepatocellular carcinoma after liver transplantation

A Quantitative Assessment Model of T-Cell Immune Function for Predicting Risks of Infection and Rejection During the Early Stage after Liver Transplantation

Peripheral Blood CD 4 + Cell ATP Activity Measurement to Predict HCC Recurrence Post‐ DCD Liver Transplant

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

Relation of ATP Content in CD4+ T Cells to Acute Rejection after Liver Transplantation

Application of ImmuKnow immune cell function assay in monitoring of immune function after renal transplantation

The Relationship Between Adenosine Triphosphate Within CD4+ T Lymphocytes and Acute Rejection after Liver Transplantation

Human leukocyte antigen-G and prognosis of liver transplantation in patients with hepatocellular carcinoma

Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation

The Unique Characteristic in Peripheral Immune Cells in Patients with Advanced Hepatocellular Carcinoma.

The Relationship Between ImmuKnow Value of Cellular Immune Function and Peripheral White Blood Cells Count and T-lymphocyte after Liver Transplantation

Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation

An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma

PP-062 Role of the Cellular Immunology Function Test in Preventing and Treating the Fungal Infection Following Liver Transplantation

Correlation research on the early stage white blood cell count and ATP value in CD4+T cell by ImmuKnow method after liver transplantation

Persistently Low Immunereactivity As Determined by PHA-Induced ATP Release is Associated with Inferior Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Liver Transplantation for Hepatocellular Carcinoma: A Prognostic Model Incorporating Pretransplant Inflammatory Cytokines.

Blood Indices and Circulating Tumor Cells for Predicting Metastasis of Hepatocellular Carcinoma after Liver Transplantation

Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry